Identification of the Binding Site of Bupropion on Serotonin Type 3A Receptors

Abstract

Bupropion is an FDA approved medication marketed as an anti-depressant, smoking-cessation, and weight loss drug. Presently, the known effects of bupropion include inhibition of norepinephrine and dopamine reuptake, as well as inhibition of cation-selective Cys-loop ion channels like nicotinic acetylcholine and serotonin type 3 A (5-HT3A) receptors. The present study focuses on bupropion's inhibitory capacity with regard to the 5-HT3A receptor. 5-HT3R is a member of the pentameric ligand-gated ion channel superfamily, which also includes nicotinic acetylcholine, γ-aminobutyric acid type A (GABAA), and glycine receptors. These channels are made up of five homologous subunits around a central ion channel pore. Each subunit is divided into extracellular, transmembrane, and intracellular domain. Dysfunction within this superfamily has been linked to neurological disorders such as anxiety, depression, epilepsy, Alzheimer's, and Parkinson's Disease. Currently, the 5-HT3receptor is targeted clinically by anti-emetics and irritable bowel syndrome treatments, but the receptor could potentially become a target for the treatment of anxiety, psychosis, bipolar disorder, and several other neurological disorders. We engineered amino acids in the α-helical M2 and M3 transmembrane segments near the M2M3 loop that is located at the interface of transmembrane and extracellular domains. We used docking studies and site-directed mutagenesis to analyze potential binding site residues for bupropion. Two-electrode voltage-clamp recordings were used to examine the effect of mutations on bupropion inhibition of these engineered 5-HT3A channels expressed in Xenopus oocytes.